



8TH SYSTEMIC SCLEROSIS WORLD CONGRESS

MARCH 14-16, 2024
PRAGUE, CZECH REPUBLIC

www.worldsclerofound.org

SCIENTIFIC PROGRAMME

THURSDAY, MARCH 14

12:00
Registration opens

PRE-CONGRESS PRACTICAL SESSIONS

13:30-15:00 First slot pre-congress practical sessions
15:15-16:45 Second slot pre-congress practical sessions
Coffee break from 15:00 to 15:15.

PRACTICAL SESSION 1 Room 220
DIAGNOSIS, CLASSIFICATION AND THERAPY OF SCLEROSING SKIN DISEASES
Convenor: **Thomas Krieg (Germany)**

PRACTICAL SESSION 2 Room 221
2024: OVERALL USE OF ULTRASONOGRAPHY IN SSc (SKIN, LUNG, JOINTS, TENDONS)
Convenor: **Nemanja Damjanov (Serbia)**

PRACTICAL SESSION 3 Room 222
HOW TO MANAGE SKIN ULCERS
Convenor: **Michael Hughes (UK)**

PRACTICAL SESSION 4 Terrace 2A
CAPILLAROSCOPY
Convenor: **Arianne Herrick (UK)**

PRACTICAL SESSION 5 Room 223
HRCT IN PRACTICE
Convenor: **Roberta Eufrasia Ledda (Italy)**

From 10:30 to 16:30 North Hall
COURSE WSF/SCTC MRSS-TRAINING AND STANDARDIZATION
Convenor: **Dan Furst**
Teachers: **D Furst (USA), M Matucci-Cerinic (Italy), D Khanna (USA), L Czirjak (Hungary), F Del Galdo (UK), Y Allanore (France), C Denton (UK)**

17:00-17:30 Forum Hall
GSK SATELLITE SYMPOSIUM

17:30-18:00 Forum Hall
OPENING

18:00-19:00 Forum Hall
OPENING LECTURES

- 18:00-18:20
Basic Lecture
C Chizzolini (Switzerland)

- 18:20-18:40
Clinical Lecture
M Mayes (USA)

- 18:40-19:00
Patient lecture: is it time to implement patient care through patient education
S Farrington (UK)

19:00 Zoom room, first floor
GET TOGETHER

FRIDAY, MARCH 15

08:00-09:00 SESSION 1 - ILD

Forum Hall

- 08:00-08:20
The lung in SSc from the pulmonology point of view
E Renzoni (UK)
- 08:20-08:40
The role of lung HRCT in SSc
H Prosch (Austria)
- 08:40-08:50
OC 1 - The incidence and risk factors for new onset of interstitial lung disease in SSc: a sensitivity analysis from EUSTAR cohort study
L Petelytska et al (Switzerland)
- 08:50-09:00
OC 2 - Peripheral blood gene expression profiling shows predictive significance for the course of interstitial lung disease in SSc
S Assassi et al (USA)

09:00-10:00 SESSION 2 - HEART

Forum Hall

- 09:00-09:20
What should be known by a rheumatologist about SSc heart disease
S Plein (UK)
- 09:20-09:40
Decision tree for the right investigation to decipher SSc heart disease
L Ross (Australia)
- 09:40-09:50
OC 3 - Identification of serum protein biomarkers associated with cardiac magnetic resonance imaging-defined subclinical cardiovascular abnormalities in SSc patients characterise inflammation
R Shukla et al (UK)
- 09:50-10:00
OC 4 - Unraveling cardiac fibrosis through multi-omics analysis: DYSF, MXRA5, and FOXF1 as promising targets
I Kocherova et al (Switzerland)

10:00-10:30 COFFEE BREAK

10:30-12:00 SESSION 3 - VASCULAR/RAYNAUD/SKIN

Forum Hall

- 10:30-10:50
May we define a unified vascular phenotype in SSc (from RP to major vascular complications)
J Pauling (UK)
- 10:50-11:10
From capillaroscopy to modern tools to assess the Microcirculation derangement in SSc
V Smith (Belgium)
- 11:10-11:30
Skin assessment in SSc beyond mRSS: clinical, pathological, molecular and imaging measurement of skin fibrosis
C Denton (UK)
- 11:30-11:40
OC 5 - The evaluation of lower extremities arterial disease in SSc patients through rheumatologist-vascular surgeon multidisciplinary management: preliminary data from an Italian single center
M G Lazzaroni et al (Italy)
- 11:40-11:50
OC 6 - Artificial intelligence based Raynaud's quantification Index (ARTIX ©): an objective mobile-based tool for patient-centred assessment of Raynaud's severity
M Di Battista et al (UK)
- 11:50-12:00
OC 7 - Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein in systemic sclerosis patients: biomarker potential for vascular calcification and inflammation
J Potjewijd et al (Netherlands)

12:00-13:30 BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

Forum Hall

13:30-14:30 POSTER SESSION & LUNCH

14:30-16:00 JANSSEN SATELLITE SYMPOSIUM

Forum Hall

FRIDAY, MARCH 15

16:00-16:30

LECTURE ON PAH

New strategies and developments in SSc-PAH

A Ghofrani (Germany)

Forum Hall

16:30-17:00 COFFEE BREAK

17:00-17:40

PARALLEL SESSION 4 - GI

Forum Hall

• 17:00-17:20

The GI from the rheumatology point of view

Z McMahan (USA)

• 17:20-17:30

OC 8 - Distinct clinical trajectories of gastrointestinal progression among patients with SSc

J Perin et al (USA)

• 17:30-17:40

OC 9 - Fecal Microbiota Transplantation in patients with SSc and lower gastrointestinal tract symptoms: the ReSScue phase 2 randomized clinical trial

H Fretheim et al (Norway)

17:40-19:00

PARALLEL SESSION 5 - CLINICAL

Very early SSc & pre SSc

Forum Hall

• 17:40-18:00

Where do we stand from the pathogenetic point of view

M Kuwana (Japan)

• 18:00-18:20

Where do we stand from the clinical point of view

S Bellando-Randone (Italy)

• 18:20-18:30

OC 10 - Deconvolution of metabolic biomarker signatures of Very Early Diagnosis of SSc (VEDOSS) and established disease: Exploratory metabolic biomarkers of fast progressors

S Kim et al (USA)

• 18:30-18:40

OC 11 - Exploring the very early diagnosis of systemic sclerosis (VEDOSS) criteria usage in the real-world: a multinational survey of rheumatologists

D Twigg et al (Switzerland)

• 18:40-18:50

OC 12 - Pulmonary involvement in very early systemic sclerosis (VEDOSS): report from a single center

M Neto et al (Portugal)

• 18:50-19:00

OC 13 - Immunosuppressive treatment alone versus immunosuppressive treatment plus oral glucocorticoids for skin fibrosis in early diffuse SSc patients. A target trial emulation study from the EUSTAR database

M Iudici et al (Switzerland)

17:00-19:10

PARALLEL SESSION 6 - BASIC

South Hall 2B

• 17:00-17:30

The role of interferon

F Barrat (USA)

• 17:30-18:00

Omics in 2024 to address the challenges in SSc

R Kramann (Germany)

• 18:00-18:10

OC 14 - Type I Interferon activation of monocytes in SSc is cGAS-STING dependent and can be directly induced by dermal fibroblasts: a promising therapeutic target for SSc

S Di Donato et al (UK)

• 18:10-18:20

OC 15 - Transcriptomes and open chromatin landscapes implicate transcription factors regulating injury and repair phenotypes in SSc endothelial cells

M Huang et al (USA)

• 18:20-18:30

OC 16 - Paired transcriptomic analysis of transitional B cells in SSc highlights defective peripheral tolerance

C Beesley et al (UK)

FRIDAY, MARCH 15

• 18:30-18:40
OC 17 - AM1476 - A Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Both Pulmonary and Dermal Fibrosis in the Chronic Graft Versus Host Disease Model of SSc
C Wenglen et al (Sweden)

• 18:40-18:50
OC 18 - GRB2 Serves as a Viable Target Against Skin Fibrosis in SSc by Regulating Endothelial Cell Apoptosis
Y Huang et al (China)

• 18:50-19:00
OC 19 - The Largest Japanese and French Genetic Studies for SSc Identified a Novel High-Risk Causal Locus and the HLA associations
Y Ishikawa et al (Japan)

• 19:00-19:10
OC 20 - A high-throughput pharmacological screening as novel in vitro approach to identify myofibroblasts targets in SSc
E Pachera et al (Switzerland)

20:30
CONGRESS DINNER
 (Transfer from Holiday Inn at 20:00)

SATURDAY, MARCH 16

07:30-08:30
BREAKFAST MEET THE EXPERT
Coordinator: L Czirjak (Hungary)

How to treat SSc Room 221
M Mayes (USA)

Vascular involvement in SSc Room 222
J Pauling (UK)

What is the role of the autoantibodies in management of SSc Room 223
M Kuwana (Japan)

Clinical approach to the follow up of internal organ manifestations in SSc Room 224
S Proudman (Australia)

Modern approach to the treatment for SSc-PAH Room 225
J Seibold (USA)

08:00-09:30 **South Hall 2B**
PARALLEL SESSION 7 BASIC

• 08:00-08:30
 The role of TGFbeta today in SSc
R Lafyatis (USA)

• 08:30-08:40
OC 21 - Primary cilia of SSc dermal fibroblasts are disrupted by downregulation of Caveolin-1 and aberrant activity of Aurora A Kinase, independent of Transforming Growth Factor Beta
R Wells et al (UK)

• 08:40-08:50
OC 22 - miR-3606-3p alleviates skin fibrosis by suppressing fibroblast inflammation and migration via inhibiting GAB1 and ITGAV
Y Chen et al (China)

• 08:50-09:00
OC 23 - Reticularized skin phenotype in SSc- potential mediators
S Chenguiti Fakhouri et al (Germany)

SATURDAY, MARCH 16

• 09:00-09:10

OC 24 - Development of pulmonary hypertension-like occlusive vasculopathy in interleukin-13 transgenic mice

J Wax et al (Germany)

• 09:10-09:20

OC 25 - Unraveling the unexpected impacts of IL-6 on pulmonary vasculopathy and cytokine dysregulation in experimental SSc

A Mehrpouyan et al (Germany)

• 09:20-09:30

OC 26 - Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population

C Padilla et al (USA)

08:30-09:30

Forum Hall

PARALLEL SESSION 8 - ORAL PRESENTATIONS

• 08:30-08:40

OC 27 - Interferon Score as a novel trial enrichment tool to predict clinical trial outcomes in patients with Limited Cutaneous SSc

S Di Donato et al (UK)

• 08:40-08:50

OC 28 - Results from outcome selection for an FDA- and EMA-acceptable Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project

A Lescoat et al (France)

• 08:50-09:00

OC 29 - DecreaSSc: an observational study to assess the validity of home monitoring to detect progression of interstitial lung disease in SSc

A Velauthapillai et al (Netherlands)

• 09:00-09:10

OC 30 - Best clinical practice in the treatment of juvenile SSc: expert panel guidance - The result of the International Hamburg Consensus Meeting December 2022

I Foeldvari et al (Germany)

• 09:10-09:20

OC 31 - Cigarette Exposure In Systemic Sclerosis: Impact On Autoantibody Expression And Disease Manifestations: An Analysis Of The EUSTAR Cohort

J Ciaffi et al (Italy)

• 09:20-09:30

OC 32 - Incident Interstitial Lung Disease in SSc in the EUSTAR Database: increased risk of mortality despite less functional progression

C Bruni et al (Italy)

09:30-10:30

Forum Hall

PARALLEL SESSION 9 - ORAL PRESENTATIONS

• 09:30-09:40

OC 33 - Evaluating the robustness of 2D and 3D deep learning-based models for diagnosing idiopathic pulmonary fibrosis within an ILD population under different CT imaging protocols

G Hyun Kim et al (USA)

• 09:40-09:50

OC 34 - Recommendations for the execution and reporting of skin ultrasound in SSc: an international collaboration under the WSF skin ultrasound group

T Santiago et al (Portugal)

• 09:50-10:00

OC 35 - Differentiation between 'scleroderma' with 'non-scleroderma' patterns in nailfold capillary microscopy: is artificial intelligence here applicable?

V Korendovych et al (Germany)

• 10:00-10:10

OC 36 - Comparing Deep Neural Network Analysis to Modified Rodnan Skin Score in a Trial of Belumosudil for SSc Patients

B Gunes et al (USA)

• 10:10-10:20

OC 37 - Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Patients with SSc, Mixed Connective Tissue Disease and Inflammatory Myopathy

R Fairchild et al (USA)

• 10:20-10:30

OC 38 - Detection of Scleroderma Facial Features by Artificial Intelligence: A pilot study

Y Suliman et al (United Arab Emirates)

SATURDAY, MARCH 16

09:30-10:30 South Hall 2B PARALLEL SESSION 10 - ORAL PRESENTATIONS

• 09:30-09:40
OC 39 - Drivers of disease burden in patients with SSc reported by the SclerOD Questionnaire - a cross-sectional analysis across clinical and demographic subgroups
S Muraru et al (Switzerland)

• 09:40-09:50
OC 40 - Early characterization of renal impairment in patients with SSc by multi-parametric magnetic resonance quantitative imaging
H He et al (China)

• 09:50-10:00
OC 41 - Efficiency of annual pulmonary arterial hypertension screening by echocardiography in patients with SSc
Y Shirai et al (Japan)

• 10:00-10:10
OC 42 - Clinical significance of anti-Ro/SSA antibodies in patients with SSc: a study from the EUSTAR database
B Burja et al (Switzerland)

• 10:10-10:20
OC 43 - Treatment regimens and mortality in SSc-associated pulmonary arterial hypertension in light of the 2022 ESC/ERS Guidelines
H Jenssen Bjørkekjæ et al (Norway)

• 10:20-10:30
OC 44 - Predictors of SSc-related primary heart involvement at cardiac magnetic resonance: a monocentric retrospective study
V Batani et al (Italy)

10:30-11:00 COFFEE BREAK

11:00-11:30 Forum Hall
LECTURE
Biomarkers in SSc, input for clinical practice and RCT
S Assassi (USA)

11:30-12:00 Forum Hall
BOEHRINGER INGELHEIM ROUND TABLE

12:00-12:30 Forum Hall
MSD SATELLITE SYMPOSIUM

12:30-13:00 Forum Hall
MALLINCKRODT SATELLITE SYMPOSIUM

13:00-14:00 POSTER SESSION & LUNCH

14:00-15:30 Forum Hall
SESSION 11 - TOP OF SSc SCIENCE - BEST FROM JOURNALS

• *Journal Scleroderma Related Disorders*
Primary SSc heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. (J Scleroderma Relat Disord. 2022;7:24)
C Bruni et al (Italy)

• *Lancet Rheumatology*
MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with SSc: a prospective cohort study
F Del Galdo (UK)

• *Nature Reviews Rheumatology*
State-of-the-art evidence in the treatment of SSc
J Pope (Canada)

15:30-16:50 Forum Hall
SESSION 12 - THERAPY

• 15:30-15:50
New EULAR recommendations for SSc management
F Del Galdo (UK)

• 15:50-16:10
EULAR/ERS guidelines for SSc ILD management
Video presentation: **A Hoffman-Vold (Norway)**
Discussant: **O Distler (Switzerland)**

• 16:10-16:30
ACR guidelines for treatment of SSc ILD
E Bernstein (USA)

• 16:30-16:40
OC 45 - Rituximab retention rate in SSc: a real-life Italian multicenter study
G De Luca et al (Italy)

SATURDAY, MARCH 16

- 16:40-16:50

OC 46 - Changes in treatment patterns and their influence on the outcome of SSc-interstitial lung disease (SSc-ILD) patients: an EUSTAR analysis

C Campochiaro et al (Italy)

- 16:50-17:50

SESSION 13 - THERAPY

Forum Hall

- 16:50-17:10

New approaches to disease modifications in SSc

D Khanna (USA)

- 17:10-17:30

Is SSc a relevant target for CartT cell therapy?

G Schett (Germany)

- 17:30-17:40

OC 47 - 399 - Chasing CARs: Clinical Follow Up Data on disease activity, serological markers and organ involvement of patients with severe SSc after treatment with CD19-targeting CAR T cells

J Auth et al (Germany)

- 17:40-17:50

OC 48 - 94 - Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy

D Rimar et al (Israel)

- 17:50-18:15

WRAP UP LECTURE

L Chung (USA) & J Distler (Germany)

Forum Hall

- 18:15

CLOSING REMARKS

PRE-CONGRESS PRACTICAL SESSIONS

Pre-congress Practical Sessions will be held on **Thursday, March 14**, for registered participants only. **Reservation is requested.** Left places can be booked at the "Onsite Registration" desk in the registration area.

Coordinator: Phil Clements (USA)

Practical Sessions will be repeated twice in the following times:
13:30-15:00 First slot pre-congress practical sessions
15:15-16:45 Second slot pre-congress practical sessions
Coffee break from 15:00 to 15:15.

PRACTICAL SESSION 1
Diagnosis, Classification and Therapy
of Sclerosing skin diseases
Convenor: Thomas Krieg

Room 220

Introduction
T Krieg (Germany)

Sclerosing skin diseases -what is required for a correct diagnosis?
P Moinzadeh (Germany)

Update on therapy for scleredema and scleromyxedema
F Rongioletti (Italy)

Classification and new therapeutic approaches for localized scleroderma
A Saracino (Australia)

How to treat skin fibrosis and Digital Ulcerations in SSc? A practical approach
Y Asano (Japan)

PRACTICAL SESSION 2
2024: Overall use of Ultrasonography in SSc
(skin, lung, joints, tendons)
Convenor: Nemanja Damianov

Room 221

13:30 & 15:15
Ultrasonography of skin in SSc
T Santiago (Portugal)

13:50 & 15:35
Ultrasonography of lungs in SSc
L Gargani (Italy)

14:10 & 15:55
Ultrasonography of joints in SSc
N Damjanov (Serbia)

14:30 & 16:15
Discussion
All speakers

PRACTICAL SESSION 3
How to manage skin Ulcers
Convenor: Michael Hughes

Room 222

13:30 & 15:15
Introduction, the importance of the team work
M Hughes (UK)

13:35 & 15:20
Digital vascular anatomy and SSc Vasculopathy
C Campochiaro (Italy)

13:45 & 15:30
Medical evaluation of DUs: definition, categorisation, classification
C Bruni (Italy)

13:55 & 15:40
Nurse assessment of Dus
K El Aoufy (Italy)

14:05 & 15:50
The overall WSF guidelines for the management of DU in SSc
M Hughes (UK)

14:15 & 16:00

Local management of Dus

B Alcacer-Pitarch (UK)

14:25 & 16:10

Pharmacological management of Dus

D Giuggioli (Italy)

14:35 & 16:20

Q&A: discussion on the approach and treatment of Dus in SSc

All faculty

14:50-16:35

Closing remarks and future research agenda

M Hughes (UK)

PRACTICAL SESSION 4

Capillaroscopy

Convenor: Ariane Herrick

Terrace 2A

13:30 & 15:15

Welcome and introduction

A Herrick (UK)

13:35 & 15:20

Indications for nailfold capillaroscopy, and how to acquire high quality images in clinical practice and in research

A Herrick (UK)

13:45 & 15:30

Interpreting nailfold capillaroscopy images: normal versus abnormal

V Smith (Belgium)

14:00 & 15:45

Applied nailfold videocapillaroscopy: live demonstration with patients

M Cutolo (Italy)

14:15 & 16:00

Hands-on practice (small group teaching) using different nailfold capillaroscopy methods (videocapillaroscopy, dermatoscope, USB microscope). All participants will have the opportunity to gain experience in acquiring and interpreting images from patients with systemic sclerosis, using the different capillaroscopic devices.

Tutors: D Furst (USA), M Matucci-Cerinic (Italy), D Khanna (USA), L Czirjak (Hungary), F Del Galdo (UK), Y Allanore (France), C Denton (UK)

14:55 & 16:00

Summing up

PRACTICAL SESSION 5

HRCT in practice

Convenor: Roberta Eufrasia Ledda (Italy)

Room 223

From 10:30 to 16:30

COURSE WSF/SCTC MRSS-TRAINING AND STANDARDIZATION

Convenor: Dan Furst

Teachers: D Furst (USA), M Matucci-Cerinic (Italy), D Khanna (USA), L Czirjak (Hungary), F Del Galdo (UK), Y Allanore (France), C Denton (UK)

North Hall

- 10:30-11:00 - Registration
- 11:00-11:45 - Lecture on mRSS and demo
- 11:45-13:30 - First round of scoring
- 13:30 - Evaluation
- 14:00 - Lunch
- 14:45 -15:30 - Retraining and rescoring
- 15:30-16:30 - Final evaluation

The course is fully-booked.



SATELLITE SYMPOSIA

THURSDAY MARCH 14

GSK SATELLITE SYMPOSIUM

Forum Hall

17:00-17:30

NEW PATHS, NEW CROSSROADS: SEEING INTO SYSTEMIC SCLEROSIS

• 17:00-17:05

Setting the Scene:

Challenges and unmet needs in SSc-ILD

C Denton (UK)

• 17:05-17:20

Research in review: Latest findings on SSc-ILD

C Denton (UK), J Distler (Germany)

• 17:20-17:30

Audience discussion and feedback

FRIDAY MARCH 15

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

Forum Hall

12:00-13:30

**SYSTEMIC SCLEROSIS IS MORE THAN SKIN DEEP:
EXPLORING UNMET NEEDS AND FUTURE TREATMENT
DIRECTIONS**

• 12:00-12:05

Introduction

O Distler (Switzerland)

• 12:05-12:20

Systemic sclerosis: a systemic disease with a high burden

Live panel discussion with:

O Distler (Switzerland), D Khanna (USA), V Smith (Belgium)

• 12:20-12:45

Addressing unmet needs in patient care in 2024: a work in progress

Live panel discussion with:

O Distler (Switzerland), D Khanna (USA), V Smith (Belgium)

• 12:45-13:10

New concepts in the pathogenesis of SSc and their relevance for drug development

Live panel discussion with:

O Distler (Switzerland), D Khanna (USA), V Smith (Belgium)

• 13:10-13:30

Q&A

O Distler (Switzerland), D Khanna (USA), V Smith (Belgium)

FRIDAY MARCH 15

JANSSEN SATELLITE SYMPOSIUM

Forum Hall

14:30-16:00

PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: MULTIDISCIPLINARY CARE OF A COMPLEX DISEASE

Chairpersons: F Del Galdo (UK), P Jansa (Czech Republic)

• 14:30-14:35

Welcome and introduction
P Jansa (Czech Republic)

• 14:35-14:55

Screening or early detection of PAH in SSc patients
D Giuggioli (Italy)

• 14:55-15:35

Multidisciplinary care and proactive treatment strategies for SSc-PAH
H Leuchte (Germany), S Gaine (Ireland)

• 15:35-15:50

Panel discussion and audience questions
All

• 15:50-16:00

Key messages and closing remarks
F Del Galdo (UK)

SATURDAY MARCH 16

BOEHRINGER INGELHEIM ROUND TABLE DISCUSSION

Forum Hall

11:30-12:00

HOW CAN WE IMPROVE COMMUNICATION BETWEEN PHYSICIANS AND PATIENTS WITH SSC?

• 11:30-11:35

Welcome and introduction: What research tells us about the communication needs of patients with SSc
M Kuwana (Japan)

• 11:35-11:55

Sharing thoughts across the communication gap: What do patients want to know, and how do they want to hear it?
C Denton (UK), Dinesh Khanna (USA), M Kuwana (Japan), S Farrington (UK), I Galletti (Italy)

• 11:55-12:00

Conclusion and future perspectives: Working together towards the ideal consultation
D Khanna (USA), S Farrington (UK), I Galletti (Italy)

SATURDAY MARCH 16

MSD SATELLITE SYMPOSIUM

Forum Hall

12:00-12:30

THE ROLE OF THE KERATINOCYTE IN PATHOGENESIS OF SYSTEMIC SCLEROSIS AND IMPLICATIONS FOR NOVEL DRUG DEVELOPMENT

- 12:00-12:10

The role of the keratinocyte in pathogenesis of Systemic Sclerosis

F Del Galdo (UK)

- 12:10-12:20

Novel MOAs and Systemic Sclerosis with interstitial lung disease

D Khanna (USA)

- 12:20-12:30

Question and Answer Session

F Del Galdo (UK), D Khanna (USA)

MALLINCKRODT SATELLITE SYMPOSIUM

Forum Hall

12:30-13:00

ECP: AN IMMUNOMODULATORY THERAPEUTIC APPROACH IN SSC

- 12:30-12:40

Proposed MOA of ECP

- 12:40-12:55

ECP in SSc patients: Experiences from the clinical practice

- 12:55-13:00

Discussion of presented topics

Speakers to be announced soon

PATIENT CONGRESS PROGRAMME

FRIDAY, MARCH 15

Time	Session title	Type of session
09:00 09:30	Patient Congress Opening Session	Plenary
09:30 10:30	Decoding Drug Development: Patient Organisation Engagement Across the Lifecycle	Plenary
10:30 11:00	Break	
11:00 12:00	What's new in Interstitial Lung Diseases?	Plenary
	System Sclerosis: one or many diseases?	Breakout
	What's new in Pulmonary Arterial Hypertension?	Breakout
	Growing Up with Systemic Sclerosis: Navigating the Transition to Adulthood	Breakout
12:00 13:00	Lunch	
13:00 14:00	Mind Matters: Tackling Mental Health in the SSc Journey	Plenary
	Bump and Beyond: Navigating Pregnancy with Systemic Sclerosis	Breakout
	Facing SSc Together: Exploring Quality of Life in Men with Systemic Sclerosis	Breakout
	Handy Solutions: Dealing with Hand Changes Like a Boss	Breakout
14:00 14:15	Break	
14:15 15:45	Cutting-edge Care: Unpacking the Latest Clinical Recommendations for systemic Sclerosis Treatment	Plenary
16:00 17:00	Session for Czech attendees: The effect of stress on autoimmunity (Czech language only)	Plenary session for Czech attendees

SATURDAY, MARCH 16

Time	Session title	Type of session
09:00 10:00	Gut Check: Navigating the Intestinal Tract and Microbiome in the World of Systemic Sclerosis	Plenary
10:00 10:15	Break	
10:15 11:15	Fatigue, invisible but heavy	Plenary
	Transplants in Systemic Sclerosis	Breakout
	Sclero-ID	Breakout
	Why do we keep on suppressing the immune system?	Breakout
11:15 12:00	Brunch	
12:00 13:00	Get Moving: Reclaiming What Systemic Sclerosis Took Away	Plenary
	How to see the body through a videocapillaroscopy?	Breakout
	Life Hacks: Navigating Everyday Wins with Systemic Sclerosis	Breakout
	How to say "You have Systemic Sclerosis"?	Breakout
13:00 13:15	Break	
13:15 14:00	Breaking Ground: Exploring the Latest Frontiers in Systemic Sclerosis Research	Plenary
14:00 14:45	Patient Congress Closing Session	Plenary
14:45	Farewell drink	



Organizing Secretariat



AIM Group International

Florence Office

Viale G. Mazzini, 70

50132 Florence, Italy

ph. +39 055 233881

ssc2024@aimgroup.eu

www.worldsclerofound.org